Form 4: Tarsus Pharmaceuticals Director William Link Reports Routine Equity Compensation and Ownership Changes

Tarsus Pharmaceuticals, Inc. Director Dr. William J. Link filed a Form 4 detailing the settlement of vested Restricted Stock Units and the grant of new stock options and RSUs, reflecting standard equity compensation.

Summary

• Dr. William J. Link, a Director of Tarsus Pharmaceuticals, Inc. (TARS), reported several transactions related to his beneficial ownership.
• On June 13, 2025, Dr. Link acquired 3,350 shares of Tarsus Pharmaceuticals common stock through the settlement of vested Restricted Stock Units (RSUs).
• Following this transaction, Dr. Link's direct beneficial ownership of common stock increased to 170,448 shares.
• Additionally, Dr. Link indirectly beneficially owns 10,446 shares through Link Family Enterprise, LP, where he is the controlling member.
• On June 12, 2025, Dr. Link was granted 4,540 stock options with an exercise price of $40.95 per share.
• These stock options are scheduled to vest in full on June 12, 2026, subject to his continuous service as a non-employee director, and will expire on June 11, 2035.
• Also on June 12, 2025, Dr. Link received a grant of 2,954 Restricted Stock Units (RSUs).
• These newly granted RSUs are set to vest in full on June 12, 2026, contingent upon his continuous service.
• The 3,350 RSUs that settled on June 13, 2025, were originally granted on June 13, 2024, as part of his compensation for service as a non-employee director.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a director, aligning their interests with shareholders. It's a standard disclosure and does not suggest any negative operational or financial issues, nor does it provide significant new positive information beyond the expected course of business.

Positives

• The grant of new stock options and Restricted Stock Units to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The settlement of vested RSUs increases the director's direct ownership in the company, demonstrating continued commitment.

Industry Context

This Form 4 filing details routine equity compensation for a director, which is a common practice across industries to align the interests of company leadership with shareholders. It does not provide broader industry trends or competitive insights.

Related Party Transactions

• Dr. William J. Link indirectly beneficially owns 10,446 shares through Link Family Enterprise, LP, where he is the controlling member, indicating a related party relationship.

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's financial interests with shareholder value creation, potentially leading to more favorable long-term decision-making.

Next Steps

• Continued service by Dr. William J. Link as a non-employee director for the vesting of the newly granted stock options and Restricted Stock Units.

Key Dates

Recommendation

Keywords

Tarsus Pharmaceuticals, TARS, SEC Form 4, insider transaction, beneficial ownership, stock options, restricted stock units, RSU, equity compensation, director, William J. Link